Specialists have warned that the approval of a glucagon-like peptide (GLP-1) receptor agonist weight-loss tablet could make it a target for online fraud and counterfeit medicines. Following its introduction into
The Medicines and Healthcare products Regulatory Agency (MHRA) has raised a safety warning following reports of rare cases of iatrogenic botulism associated with botulinum toxin type A (BoNT-A) products. The
The Medicines and Healthcare products Regulatory Agency (MHRA), Advertising Standards Authority (ASA), and the General Pharmaceutical Council (GPhC) have released a warning to businesses against promoting newly licensed medicines and
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) have announced a new liaison programme. The agencies share that the roles aim to enhance day-to-day collaboration, support scientific exchange and enable
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first glucagon-like peptide-1 (GLP-1) receptor agonist weight-loss tablet for use in the UK. The once-daily semaglutide tablet, marketed by
The Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit has arrested two individuals following a suspected illegal weight-loss drug operation. The arrests took place after raiding a country estate near Northampton
The British College of Aesthetic Medicine (BCAM) is urging the public to exercise caution over the increasing promotion of injectable peptide treatments. BCAM states that these treatments are commonly promoted
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched an investigation into UK clinics following reports that some are promoting unregulated, experimental peptides. According to The Guardian, the clinics
Officers from the Criminal Enforcement Unit (CEU) of The Medicines and Healthcare products Regulatory Agency (MHRA) have raided premises involved in the manufacture and sale of unlicensed weight-loss medicines. The MHRA reports
The Medicines and Healthcare products Regulatory Agency (MHRA), working alongside the Advertising Standards Authority (ASA) and the General Pharmaceutical Council (GPhC), has released an updated Enforcement Notice this week to